FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough

The FDA is delaying its decision on Merck’s gefapixant by at least a few months to “provide time for a full review of the submission,” the company revealed in an SEC filing. The agency, which originally set a PDUFA date for Dec. 21, now expects to make a decision by March 21.